NASDAQ: ABOS

Acumen Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

The consensus among 2 Wall Street analysts covering (NASDAQ: ABOS) stock is to Strong Buy ABOS stock.

Out of 2 analysts, 1 (50%) are recommending ABOS as a Strong Buy, 1 (50%) are recommending ABOS as a Buy, 0 (0%) are recommending ABOS as a Hold, 0 (0%) are recommending ABOS as a Sell, and 0 (0%) are recommending ABOS as a Strong Sell.

If you're new to stock investing, here's how to buy Acumen Pharmaceuticals stock.

(NASDAQ: ABOS) Acumen Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 245.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.38%.

Acumen Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ABOS's revenue for 2028 to be $1,593,916,510, with the lowest ABOS revenue forecast at $1,593,916,510, and the highest ABOS revenue forecast at $1,593,916,510. On average, 1 Wall Street analysts forecast ABOS's revenue for 2029 to be $3,375,882,726, with the lowest ABOS revenue forecast at $3,375,882,726, and the highest ABOS revenue forecast at $3,375,882,726.

In 2030, ABOS is forecast to generate $7,257,637,182 in revenue, with the lowest revenue forecast at $7,257,637,182 and the highest revenue forecast at $7,257,637,182.

According to 2 Wall Street analysts that have issued a 1 year ABOS price target, the average ABOS price target is $11.50, with the highest ABOS stock price forecast at $15.00 and the lowest ABOS stock price forecast at $8.00.

On average, Wall Street analysts predict that Acumen Pharmaceuticals's share price could reach $11.50 by Mar 27, 2025. The average Acumen Pharmaceuticals stock price prediction forecasts a potential upside of 263.92% from the current ABOS share price of $3.16.

(NASDAQ: ABOS) forecast ROE is -27.91%, which is considered weak.